by Paul | 9th February 2024 | News
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need The initial trial of OK-101 to treat NCP is designed as a randomized,... by admin | 11th May 2023 | News
11 May 2023 The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), announces that it has delayed the date on which the cancellation of its ordinary shares of no par value each (“Ordinary Shares“) from listing on the standard segment of the FCA’s...
